TBC 609

Drug Profile

TBC 609

Alternative Names: TBC609

Latest Information Update: 05 Feb 2008

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Encysive Pharmaceuticals
  • Class Antirheumatics; Peptides; Vascular disorder therapies
  • Mechanism of Action Vascular cell adhesion molecule inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Atherosclerosis; Ischaemic heart disorders; Multiple sclerosis; Rheumatoid arthritis

Most Recent Events

  • 20 Jul 1998 No-Development-Reported for Atherosclerosis in USA (Unknown route)
  • 20 Jul 1998 No-Development-Reported for Ischaemic heart disorders in USA (Unknown route)
  • 20 Jul 1998 No-Development-Reported for Multiple sclerosis in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top